Case report: Dramatic impact of DNA next generation sequencing results using specific targeted therapies-

Stav Cullum, Hlu Vang, Michael Glover, Howra Alammarah, Heather Morton, Nancy Pham, Mobeen Rahman, Saad A Khan

Abstract readCase Reports

In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stav CullumDivision of Oncology, Department of Medicine, Stanford Cancer Institute and Stanford University, Stanford, CA, United States.

Hlu VangDepartment of Otolaryngology/Head & Neck Surgery Divisions, Stanford University, Stanford, CA, United States.

Michael GloverDivision of Oncology, Department of Medicine, Stanford Cancer Institute and Stanford University, Stanford, CA, United States.

Howra AlammarahDivision of Oncology, Department of Medicine, Stanford Cancer Institute and Stanford University, Stanford, CA, United States.

Heather MortonDivision of Oncology, Department of Medicine, Stanford Cancer Institute and Stanford University, Stanford, CA, United States.

Nancy PhamDepartment of Radiology, Stanford University, Stanford, CA, United States.

Mobeen RahmanDepartment of Pathology, Stanford University, Stanford, CA, United States.

Saad A KhanDivision of Oncology, Department of Medicine, Stanford Cancer Institute and Stanford University, Stanford, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the era of targeted therapies, the clinical importance and utility of next-generation sequencing (NGS) has expanded significantly. Owing to the relative ease and financial feasibility of NGS, the use of personalized treatment strategies has the potential to revolutionize cancer care. In this case report, we explored the use of NGS in salivary gland carcinoma (SGC) and spindle cell neoplasm of the scalp. In our patient with SGC, NGS revealed a GPHN-ALK variant that allowed off-label treatment with alectinib, with a remarkable response in primary and metastatic foci. Similarly, the use of NGS in a cutaneous neoplasm in which no definitive diagnosis could be reached by pathology and which had progressed through standard of care treatment elucidated a PIK3CA mutation in which alpelisib was added and ultimately halted POD. Here, we discuss the use of NGS, future projections, and our recommendations.

Indexed as

ALK inhibitorDNA NGSPI3 kinase inhibitorprecision oncologyRNA NGS

Identifiers

PMID39659799

DOI10.3389/fonc.2024.1462930

PMCPMC11628483

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.